AstraZeneca

News

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for an antibody-drug conjugate and potential new targeted cancer medicine,

News

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

AstraZeneca has won the backing of NICE for its cancer immunotherapy Imfinzi for non-small cell lung cancer (NSCLC), with the drug made available via the Cancer Drugs Fund for now.

Partner Content

Partner Content

HPAPI 2019 Conference - Exclusive Interview Released with As...

HPAPI Conference 2019 - AstraZeneca Interview

News

AZ's diabetes drug Forxiga approved in EU for type 1 disease

AstraZeneca’s diabetes drug Forxiga (dapagliflozin) has been approved in the EU in patients with type 1 disease.

News

AZ backs diabetes drug Farxiga with new cardio analysis

AstraZeneca continues to make the case for its Farxiga diabetes drug, highlighting a cardiology analysis that it hopes will convince more doctors to prescribe it in a highly competitive mar

R&D

Precision medicine: AZ's Ruth March on its next steps

AstraZeneca’s senior vice-president and head of precision medicine, research & development, Ruth March, has been central to the company’s transformed approach to personalised treatment.

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

HPAPI 2019 Conference - Exclusive Interview Released with As...

AZ's diabetes drug Forxiga approved in EU for type 1 disease

AZ backs diabetes drug Farxiga with new cardio analysis

Precision medicine: AZ's Ruth March on its next steps

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks